| abstract |
The present disclosure describes anti-B7H3 antibody agents and related uses. In particular, this disclosure demonstrates the specific immunomodulatory efficacy of certain such antibodies. The present disclosure further describes particularly high affinity or separately useful antibodies and antibody agents based thereon, particularly including certain humanized and / or affinity matured versions of the 8H9 antibody. In some embodiments, provided antibody agents are useful, for example, in the treatment of cancer. In some embodiments, provided antibody agents are useful in alleviating immune suppression mediated, for example, by B7H3-positive cells. |